Ronald J Holewinski
Overview
Explore the profile of Ronald J Holewinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buckenmeyer M, Brooks E, Taylor M, Orenuga I, Yang L, Holewinski R, et al.
Cancer Res
. 2025 Jan;
PMID: 39888317
Three-dimensional (3D) in vitro cell culture models are invaluable tools for investigating the tumor microenvironment (TME). However, analyzing the impact of critical stromal elements, such as extracellular matrix (ECM), remains...
2.
van den Broek I, Fu Q, Kushon S, Kowalski M, Millis K, Percy A, et al.
Clin Mass Spectrom
. 2024 Aug;
4-5:25-33.
PMID: 39193127
Volumetric absorptive micro sampling (VAMS™) allows accurate sampling of 10 µL of blood from a minimally invasive finger prick and could enable remote personalized health monitoring. Moreover, VAMS overcomes effects...
3.
Thalalla Gamage S, Khoogar R, Manage S, Crawford M, Georgeson J, Polevoda B, et al.
bioRxiv
. 2024 Aug;
PMID: 39091849
Transfer RNA (tRNA) modifications are crucial for protein synthesis, but their position-specific physiological roles remain poorly understood. Here we investigate the impact of N4-acetylcytidine (acC), a highly conserved tRNA modification,...
4.
Bolomsky A, Ceribelli M, Scheich S, Rinaldi K, Huang D, Chakraborty P, et al.
Cancer Cell
. 2024 Jun;
42(7):1185-1201.e14.
PMID: 38906156
Multiple myeloma (MM) is an incurable plasma cell malignancy that exploits transcriptional networks driven by IRF4. We employ a multi-omics approach to discover IRF4 vulnerabilities, integrating functional genomics screening, spatial...
5.
Buckenmeyer M, Brooks E, Taylor M, Yang L, Holewinski R, Meyer T, et al.
bioRxiv
. 2024 Jun;
PMID: 38903106
The tumor microenvironment consists of resident tumor cells organized within a compositionally diverse, three-dimensional (3D) extracellular matrix (ECM) network that cannot be replicated in vitro using bottom-up synthesis. We report...
6.
Balaratnam S, Torrey Z, Calabrese D, Banco M, Yazdani K, Liang X, et al.
Cell Chem Biol
. 2023 May;
30(6):643-657.e8.
PMID: 37257453
Neuroblastoma RAS (NRAS) is an oncogene that is deregulated and highly mutated in cancers including melanomas and acute myeloid leukemias. The 5' untranslated region (UTR) (5' UTR) of the NRAS...
7.
Park W, Gray J, Holewinski R, Andresson T, So J, Carmona-Rivera C, et al.
Nat Cancer
. 2023 Mar;
4(3):419-435.
PMID: 36973439
Most tumor cells undergo apoptosis in circulation and at the metastatic organ sites due to host immune surveillance and a hostile microenvironment. It remains to be elucidated whether dying tumor...
8.
Ranek M, Oeing C, Sanchez-Hodge R, Kokkonen-Simon K, Dillard D, Aslam M, et al.
Nat Commun
. 2020 Oct;
11(1):5237.
PMID: 33082318
Proteotoxicity from insufficient clearance of misfolded/damaged proteins underlies many diseases. Carboxyl terminus of Hsc70-interacting protein (CHIP) is an important regulator of proteostasis in many cells, having E3-ligase and chaperone functions...
9.
Robinson A, Binek A, Venkatraman V, Searle B, Holewinski R, Rosenberger G, et al.
J Proteome Res
. 2020 Sep;
19(10):4163-4178.
PMID: 32966080
Proteoforms containing post-translational modifications (PTMs) represent a degree of functional diversity only harnessed through analytically precise simultaneous quantification of multiple PTMs. Here we present a method to accurately differentiate an...
10.
Parker S, Chen L, Spivia W, Saylor G, Mao C, Venkatraman V, et al.
J Proteome Res
. 2020 Mar;
19(7):2794-2806.
PMID: 32202800
Coronary artery disease remains a leading cause of death in industrialized nations, and early detection of disease is a critical intervention target to effectively treat patients and manage risk. Proteomic...